The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Mitchell A. Psotka et al.|Nature Medicine|2022Cited by 889
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trialJan Biegus, Piotr Ponikowski, Adriaan A. Voors et al.|European Heart Journal|2022Cited by 213
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE TrialMikhail Kosiborod, Adriaan A. Voors, Christiane E. Angermann et al.|Circulation|2022Cited by 142
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trialWolfram Doehner, Milton Packer, Stefan D. Anker et al.|European Heart Journal|2022Cited by 122